Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability
Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA...
Gespeichert in:
Veröffentlicht in: | Atherosclerosis 2010-09, Vol.212 (1), p.252-259 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 259 |
---|---|
container_issue | 1 |
container_start_page | 252 |
container_title | Atherosclerosis |
container_volume | 212 |
creator | Cawood, Abbie L Ding, Ren Napper, Frances L Young, Ruth H Williams, Jennifer A Ward, Matthew J.A Gudmundsen, Ola Vige, Runar Payne, Simon P.K Ye, Shu Shearman, Ciff P Gallagher, Patrick J Grimble, Robert F Calder, Philip C |
description | Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P < 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability. |
doi_str_mv | 10.1016/j.atherosclerosis.2010.05.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_753994694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915010004004</els_id><sourcerecordid>753994694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</originalsourceid><addsrcrecordid>eNqNks9u1DAQxiMEotvCKyBfKuhhFzv_fQCpqpaCVAkk4GxNnAnrJbEX21uUN-DMI3LiMZjshgr1hGQlsvObbybf5yQ5F3wluChfblcQN-hd0P30NGGVcvrGixVP0wfJQtSVXIq8zh8mC85TsZSi4CfJaQhbznleifpxcpLyIk8LkS6S32ujXYAd2ghondEMtGnZi_WHywvWeTewjfmy6UemndUEeYjYMst-_fiZsQ5iHI8FGDdjzzBE9IEZWlY7v3NH3NjoGLS3QBIt-3f-SA13PXzbY2Bg20Mz9PMRoyEmLQjBaXNQ-m7ihrWoPUKg7cwZ2_UwDBCNswcZ6j4TIUJjehPHJ8mjDvqAT-f3WfL5zfrT1dvlzfvrd1eXN0udV1lcVlg0ZA2UjW7rTlZdhTlUtZBIzok6F7oRUpStrMumo7OOS4lZrWXWpqVoIDtLnh91d95NvxXVYILGvgeLbh9UVWRS5qXMiXx1JDW5ETx2aufNAH5Ugqspa7VV97JWU9aKF4qypvpnc6d9M2B7V_03XALOZwCChr7z5D9p3HFZmsms5sRdHzkkX24NehW0wSkr41FH1Trz3yO9vqeke2MNNf-KI4at23tL5iuhQqq4-jhd0Ol-iulq0sr-AKPm7VM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>753994694</pqid></control><display><type>article</type><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</creator><creatorcontrib>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</creatorcontrib><description>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P < 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2010.05.022</identifier><identifier>PMID: 20542512</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Capsules ; Cardiology. Vascular system ; Cardiovascular ; Carotid Artery Diseases - drug therapy ; Carotid Artery Diseases - immunology ; Carotid Artery Diseases - metabolism ; Carotid Artery Diseases - pathology ; Carotid Artery Diseases - surgery ; Chi-Square Distribution ; Coronary heart disease ; Cytokines - genetics ; Dietary Supplements ; Docosahexaenoic Acids - administration & dosage ; Docosahexaenoic Acids - blood ; Double-Blind Method ; Drug Combinations ; Eicosapentaenoic Acid - administration & dosage ; Eicosapentaenoic Acid - analogs & derivatives ; Eicosapentaenoic Acid - blood ; Eicosapentaenoic Acid - metabolism ; Endarterectomy, Carotid ; England ; Fatty acid ; Female ; Foam Cells - drug effects ; Foam Cells - immunology ; Gene Expression Regulation ; Heart ; Humans ; Inflammation ; Inflammation - drug therapy ; Inflammation - immunology ; Inflammation - metabolism ; Inflammation - pathology ; Inflammation - surgery ; Inflammation Mediators - analysis ; Male ; Matrix Metalloproteinases - genetics ; Medical sciences ; Metalloproteinase ; Middle Aged ; Phospholipids - metabolism ; Plaque ; Preoperative Care ; RNA, Messenger - analysis ; Rupture, Spontaneous ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; Treatment Outcome</subject><ispartof>Atherosclerosis, 2010-09, Vol.212 (1), p.252-259</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</citedby><cites>FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.atherosclerosis.2010.05.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23239380$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20542512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cawood, Abbie L</creatorcontrib><creatorcontrib>Ding, Ren</creatorcontrib><creatorcontrib>Napper, Frances L</creatorcontrib><creatorcontrib>Young, Ruth H</creatorcontrib><creatorcontrib>Williams, Jennifer A</creatorcontrib><creatorcontrib>Ward, Matthew J.A</creatorcontrib><creatorcontrib>Gudmundsen, Ola</creatorcontrib><creatorcontrib>Vige, Runar</creatorcontrib><creatorcontrib>Payne, Simon P.K</creatorcontrib><creatorcontrib>Ye, Shu</creatorcontrib><creatorcontrib>Shearman, Ciff P</creatorcontrib><creatorcontrib>Gallagher, Patrick J</creatorcontrib><creatorcontrib>Grimble, Robert F</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P < 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Capsules</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Carotid Artery Diseases - drug therapy</subject><subject>Carotid Artery Diseases - immunology</subject><subject>Carotid Artery Diseases - metabolism</subject><subject>Carotid Artery Diseases - pathology</subject><subject>Carotid Artery Diseases - surgery</subject><subject>Chi-Square Distribution</subject><subject>Coronary heart disease</subject><subject>Cytokines - genetics</subject><subject>Dietary Supplements</subject><subject>Docosahexaenoic Acids - administration & dosage</subject><subject>Docosahexaenoic Acids - blood</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Eicosapentaenoic Acid - administration & dosage</subject><subject>Eicosapentaenoic Acid - analogs & derivatives</subject><subject>Eicosapentaenoic Acid - blood</subject><subject>Eicosapentaenoic Acid - metabolism</subject><subject>Endarterectomy, Carotid</subject><subject>England</subject><subject>Fatty acid</subject><subject>Female</subject><subject>Foam Cells - drug effects</subject><subject>Foam Cells - immunology</subject><subject>Gene Expression Regulation</subject><subject>Heart</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Inflammation - pathology</subject><subject>Inflammation - surgery</subject><subject>Inflammation Mediators - analysis</subject><subject>Male</subject><subject>Matrix Metalloproteinases - genetics</subject><subject>Medical sciences</subject><subject>Metalloproteinase</subject><subject>Middle Aged</subject><subject>Phospholipids - metabolism</subject><subject>Plaque</subject><subject>Preoperative Care</subject><subject>RNA, Messenger - analysis</subject><subject>Rupture, Spontaneous</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>Treatment Outcome</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNks9u1DAQxiMEotvCKyBfKuhhFzv_fQCpqpaCVAkk4GxNnAnrJbEX21uUN-DMI3LiMZjshgr1hGQlsvObbybf5yQ5F3wluChfblcQN-hd0P30NGGVcvrGixVP0wfJQtSVXIq8zh8mC85TsZSi4CfJaQhbznleifpxcpLyIk8LkS6S32ujXYAd2ghondEMtGnZi_WHywvWeTewjfmy6UemndUEeYjYMst-_fiZsQ5iHI8FGDdjzzBE9IEZWlY7v3NH3NjoGLS3QBIt-3f-SA13PXzbY2Bg20Mz9PMRoyEmLQjBaXNQ-m7ihrWoPUKg7cwZ2_UwDBCNswcZ6j4TIUJjehPHJ8mjDvqAT-f3WfL5zfrT1dvlzfvrd1eXN0udV1lcVlg0ZA2UjW7rTlZdhTlUtZBIzok6F7oRUpStrMumo7OOS4lZrWXWpqVoIDtLnh91d95NvxXVYILGvgeLbh9UVWRS5qXMiXx1JDW5ETx2aufNAH5Ugqspa7VV97JWU9aKF4qypvpnc6d9M2B7V_03XALOZwCChr7z5D9p3HFZmsms5sRdHzkkX24NehW0wSkr41FH1Trz3yO9vqeke2MNNf-KI4at23tL5iuhQqq4-jhd0Ol-iulq0sr-AKPm7VM</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Cawood, Abbie L</creator><creator>Ding, Ren</creator><creator>Napper, Frances L</creator><creator>Young, Ruth H</creator><creator>Williams, Jennifer A</creator><creator>Ward, Matthew J.A</creator><creator>Gudmundsen, Ola</creator><creator>Vige, Runar</creator><creator>Payne, Simon P.K</creator><creator>Ye, Shu</creator><creator>Shearman, Ciff P</creator><creator>Gallagher, Patrick J</creator><creator>Grimble, Robert F</creator><creator>Calder, Philip C</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100901</creationdate><title>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</title><author>Cawood, Abbie L ; Ding, Ren ; Napper, Frances L ; Young, Ruth H ; Williams, Jennifer A ; Ward, Matthew J.A ; Gudmundsen, Ola ; Vige, Runar ; Payne, Simon P.K ; Ye, Shu ; Shearman, Ciff P ; Gallagher, Patrick J ; Grimble, Robert F ; Calder, Philip C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-7e5b425a6bcd8f97f7e4a7819e7181841cb1916d986bfe71f099e38c93d261ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Capsules</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Carotid Artery Diseases - drug therapy</topic><topic>Carotid Artery Diseases - immunology</topic><topic>Carotid Artery Diseases - metabolism</topic><topic>Carotid Artery Diseases - pathology</topic><topic>Carotid Artery Diseases - surgery</topic><topic>Chi-Square Distribution</topic><topic>Coronary heart disease</topic><topic>Cytokines - genetics</topic><topic>Dietary Supplements</topic><topic>Docosahexaenoic Acids - administration & dosage</topic><topic>Docosahexaenoic Acids - blood</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Eicosapentaenoic Acid - administration & dosage</topic><topic>Eicosapentaenoic Acid - analogs & derivatives</topic><topic>Eicosapentaenoic Acid - blood</topic><topic>Eicosapentaenoic Acid - metabolism</topic><topic>Endarterectomy, Carotid</topic><topic>England</topic><topic>Fatty acid</topic><topic>Female</topic><topic>Foam Cells - drug effects</topic><topic>Foam Cells - immunology</topic><topic>Gene Expression Regulation</topic><topic>Heart</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Inflammation - pathology</topic><topic>Inflammation - surgery</topic><topic>Inflammation Mediators - analysis</topic><topic>Male</topic><topic>Matrix Metalloproteinases - genetics</topic><topic>Medical sciences</topic><topic>Metalloproteinase</topic><topic>Middle Aged</topic><topic>Phospholipids - metabolism</topic><topic>Plaque</topic><topic>Preoperative Care</topic><topic>RNA, Messenger - analysis</topic><topic>Rupture, Spontaneous</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cawood, Abbie L</creatorcontrib><creatorcontrib>Ding, Ren</creatorcontrib><creatorcontrib>Napper, Frances L</creatorcontrib><creatorcontrib>Young, Ruth H</creatorcontrib><creatorcontrib>Williams, Jennifer A</creatorcontrib><creatorcontrib>Ward, Matthew J.A</creatorcontrib><creatorcontrib>Gudmundsen, Ola</creatorcontrib><creatorcontrib>Vige, Runar</creatorcontrib><creatorcontrib>Payne, Simon P.K</creatorcontrib><creatorcontrib>Ye, Shu</creatorcontrib><creatorcontrib>Shearman, Ciff P</creatorcontrib><creatorcontrib>Gallagher, Patrick J</creatorcontrib><creatorcontrib>Grimble, Robert F</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cawood, Abbie L</au><au>Ding, Ren</au><au>Napper, Frances L</au><au>Young, Ruth H</au><au>Williams, Jennifer A</au><au>Ward, Matthew J.A</au><au>Gudmundsen, Ola</au><au>Vige, Runar</au><au>Payne, Simon P.K</au><au>Ye, Shu</au><au>Shearman, Ciff P</au><au>Gallagher, Patrick J</au><au>Grimble, Robert F</au><au>Calder, Philip C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>212</volume><issue>1</issue><spage>252</spage><epage>259</epage><pages>252-259</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Abstract Objective To examine n −3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Methods and results Patients awaiting carotid endarterectomy ( n = 121) were randomised to consume control capsules or n −3 PUFA ethyl ester capsules until surgery (median 21 days). The fatty acid compositions of plasma and carotid plaque phospholipids, plaque features, and expression of inflammatory genes were determined. The proportion of eicosapentaenoic acid (EPA) was higher ( P < 0.0001) in carotid plaque phospholipids in patients in the n −3 PUFA group. Plaques from patients in the n −3 PUFA group had fewer foam cells ( P = 0.0390). There were no other differences between plaques in the two groups with regard to histological characteristics or morphology. Plaque stability was not different between the two groups. However, the EPA content of plaque phospholipids was inversely associated with plaque instability ( P = 0.0209), plaque inflammation ( P = 0.0108), the number of T cells in the plaque ( P = 0.0097) and a summary score considering a range of plaque features ( P = 0.0425). Plaques from patients who received n −3 PUFAs had significantly lower levels of mRNA for matrix metalloproteinases (MMP)-7 ( P = 0.0055), -9 ( P = 0.0048) and -12 ( P = 0.0044) and for interleukin-6 ( P = 0.0395) and intercellular adhesion molecule 1 ( P = 0.0142). Conclusions Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>20542512</pmid><doi>10.1016/j.atherosclerosis.2010.05.022</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9150 |
ispartof | Atherosclerosis, 2010-09, Vol.212 (1), p.252-259 |
issn | 0021-9150 1879-1484 |
language | eng |
recordid | cdi_proquest_miscellaneous_753994694 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Administration, Oral Adult Aged Aged, 80 and over Atherosclerosis Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels Capsules Cardiology. Vascular system Cardiovascular Carotid Artery Diseases - drug therapy Carotid Artery Diseases - immunology Carotid Artery Diseases - metabolism Carotid Artery Diseases - pathology Carotid Artery Diseases - surgery Chi-Square Distribution Coronary heart disease Cytokines - genetics Dietary Supplements Docosahexaenoic Acids - administration & dosage Docosahexaenoic Acids - blood Double-Blind Method Drug Combinations Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - analogs & derivatives Eicosapentaenoic Acid - blood Eicosapentaenoic Acid - metabolism Endarterectomy, Carotid England Fatty acid Female Foam Cells - drug effects Foam Cells - immunology Gene Expression Regulation Heart Humans Inflammation Inflammation - drug therapy Inflammation - immunology Inflammation - metabolism Inflammation - pathology Inflammation - surgery Inflammation Mediators - analysis Male Matrix Metalloproteinases - genetics Medical sciences Metalloproteinase Middle Aged Phospholipids - metabolism Plaque Preoperative Care RNA, Messenger - analysis Rupture, Spontaneous T-Lymphocytes - drug effects T-Lymphocytes - immunology Treatment Outcome |
title | Eicosapentaenoic acid (EPA) from highly concentrated n −3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T17%3A47%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eicosapentaenoic%20acid%20(EPA)%20from%20highly%20concentrated%20n%20%E2%88%923%20fatty%20acid%20ethyl%20esters%20is%20incorporated%20into%20advanced%20atherosclerotic%20plaques%20and%20higher%20plaque%20EPA%20is%20associated%20with%20decreased%20plaque%20inflammation%20and%20increased%20stability&rft.jtitle=Atherosclerosis&rft.au=Cawood,%20Abbie%20L&rft.date=2010-09-01&rft.volume=212&rft.issue=1&rft.spage=252&rft.epage=259&rft.pages=252-259&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2010.05.022&rft_dat=%3Cproquest_cross%3E753994694%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=753994694&rft_id=info:pmid/20542512&rft_els_id=S0021915010004004&rfr_iscdi=true |